In contrast with the other studies, significantly longer PFS and OS (at the adjusted multivariate analysis) were found in favor of docetaxel in the 222 EGFR wild-type patients, enrolled in the TAILOR trial (Table 2), whose primary objective was to show 14% OS improvement at 1 year of docetaxel over erlotinib in EGFR wild-type NSCLC patients (37). Here, EGFR is linked to non-small cell lung carcinoma.